Active substance
Results for the substance ravulizumab
2 results
About this active substance
Ravulizumab is a monoclonal antibody used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It works by inhibiting complement C5, preventing red blood cell destruction and blood clot formation.
The medication is administered intravenously, as directed by a doctor, usually at regular intervals. It is important for patients to follow the treatment regimen and undergo regular check-ups to monitor the therapy's effectiveness.
Patients should be aware of potential side effects, such as injection site reactions, infections, or headaches. It is important to inform the doctor of any unusual symptoms.
Common side effects include headaches, infections, and injection site reactions. In rare cases, severe reactions such as meningococcal infections may occur. Patients should be informed of these risks before use.
The medication is administered intravenously, as directed by a doctor, usually at regular intervals. It is important for patients to follow the treatment regimen and undergo regular check-ups to monitor the therapy's effectiveness.
Patients should be aware of potential side effects, such as injection site reactions, infections, or headaches. It is important to inform the doctor of any unusual symptoms.
Common side effects include headaches, infections, and injection site reactions. In rare cases, severe reactions such as meningococcal infections may occur. Patients should be informed of these risks before use.